Cargando…

RNA methylation-related genes of m6A, m5C, and m1A predict prognosis and immunotherapy response in cervical cancer

PURPOSE: To investigate the prognostic value of N6-methyladenosine (m6A)-, 5-methylcytosine (m5C)-, and N1-methyladenosine (m1A)-related genes in cervical cancer (CESC) and predicting immunotherapy response. METHODS: We downloaded cervical cancer mRNA expression profiles, clinical data, and m6A, m5C...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yan, Mao, Yiwen, Wang, Caizhi, Jiang, Xuefeng, Tang, Qionglan, Wang, Lingling, Zhu, Jialei, Zhao, Mengqiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101678/
https://www.ncbi.nlm.nih.gov/pubmed/37042849
http://dx.doi.org/10.1080/07853890.2023.2190618
_version_ 1785025560897912832
author Wang, Yan
Mao, Yiwen
Wang, Caizhi
Jiang, Xuefeng
Tang, Qionglan
Wang, Lingling
Zhu, Jialei
Zhao, Mengqiu
author_facet Wang, Yan
Mao, Yiwen
Wang, Caizhi
Jiang, Xuefeng
Tang, Qionglan
Wang, Lingling
Zhu, Jialei
Zhao, Mengqiu
author_sort Wang, Yan
collection PubMed
description PURPOSE: To investigate the prognostic value of N6-methyladenosine (m6A)-, 5-methylcytosine (m5C)-, and N1-methyladenosine (m1A)-related genes in cervical cancer (CESC) and predicting immunotherapy response. METHODS: We downloaded cervical cancer mRNA expression profiles, clinical data, and m6A, m5C, m1A-related genes from public databases, and subjected them to serial bioinformatics analysis and clinical sample validation. RESULTS: Differential analysis revealed 106 methylation-related differential genes (MEDs), including 44 differentially downregulated and 62 upregulated genes. We then obtained methylation models containing 10 genes by univariate and multifactorial COX analysis. High risk genes with HR > 1 include IQGAP3, PTBP1, STAC3, CUX1, SLC2A1, and CA2, and low risk genes with HR < 1 include IGBP1, DUOX1, CHAF1A, and STAC3. We verified the accuracy of the model from inside TCGA and outside GSE39001 (AUC = 0.729). K-M analysis showed shorter survival times in the High-risk group, and Immunocytic infiltration analysis showed model genes closely associated with six immune cells. The high-risk group may benefit more effectively from immunosuppressive therapy, especially anti-CTLA-4 therapy (p < .05). We also screened nine drugs for potential treatment and verified the expression of three key genes SLC2A1, CUX1, and CA2 using immunohistochemistry and RT-qPCR experiments with clinical samples. CONCLUSION: We identified a prognostic model using m6A/m5C/m1A-related genes in cervical cancer, which can predict survival time and correlate with immune cell infiltration. Additionally, anti-CTLA-4 may be used as an immunotherapeutic agent for cervical cancer. KEY MESSAGES: Cervical cancer still has a high mortality rate, we aim to establish a strong prognostic index and new treatment goals for improving patient survival. The role of three types of RNA methylation modifications, m6A, m5C, and m1A, in cervical cancer, remains unknown. Therefore, it is essential to explore the potential molecular mechanisms of m6A, m5C, and m1A methylation regulation in cervical cancer. We also screened nine drugs for potential treatment and anti-CTLA-4 may be used as an immunotherapeutic agent for cervical cancer. We verified the expression of three key genes SLC2A1, CUX1, and CA2.
format Online
Article
Text
id pubmed-10101678
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-101016782023-04-14 RNA methylation-related genes of m6A, m5C, and m1A predict prognosis and immunotherapy response in cervical cancer Wang, Yan Mao, Yiwen Wang, Caizhi Jiang, Xuefeng Tang, Qionglan Wang, Lingling Zhu, Jialei Zhao, Mengqiu Ann Med Oncology PURPOSE: To investigate the prognostic value of N6-methyladenosine (m6A)-, 5-methylcytosine (m5C)-, and N1-methyladenosine (m1A)-related genes in cervical cancer (CESC) and predicting immunotherapy response. METHODS: We downloaded cervical cancer mRNA expression profiles, clinical data, and m6A, m5C, m1A-related genes from public databases, and subjected them to serial bioinformatics analysis and clinical sample validation. RESULTS: Differential analysis revealed 106 methylation-related differential genes (MEDs), including 44 differentially downregulated and 62 upregulated genes. We then obtained methylation models containing 10 genes by univariate and multifactorial COX analysis. High risk genes with HR > 1 include IQGAP3, PTBP1, STAC3, CUX1, SLC2A1, and CA2, and low risk genes with HR < 1 include IGBP1, DUOX1, CHAF1A, and STAC3. We verified the accuracy of the model from inside TCGA and outside GSE39001 (AUC = 0.729). K-M analysis showed shorter survival times in the High-risk group, and Immunocytic infiltration analysis showed model genes closely associated with six immune cells. The high-risk group may benefit more effectively from immunosuppressive therapy, especially anti-CTLA-4 therapy (p < .05). We also screened nine drugs for potential treatment and verified the expression of three key genes SLC2A1, CUX1, and CA2 using immunohistochemistry and RT-qPCR experiments with clinical samples. CONCLUSION: We identified a prognostic model using m6A/m5C/m1A-related genes in cervical cancer, which can predict survival time and correlate with immune cell infiltration. Additionally, anti-CTLA-4 may be used as an immunotherapeutic agent for cervical cancer. KEY MESSAGES: Cervical cancer still has a high mortality rate, we aim to establish a strong prognostic index and new treatment goals for improving patient survival. The role of three types of RNA methylation modifications, m6A, m5C, and m1A, in cervical cancer, remains unknown. Therefore, it is essential to explore the potential molecular mechanisms of m6A, m5C, and m1A methylation regulation in cervical cancer. We also screened nine drugs for potential treatment and anti-CTLA-4 may be used as an immunotherapeutic agent for cervical cancer. We verified the expression of three key genes SLC2A1, CUX1, and CA2. Taylor & Francis 2023-04-12 /pmc/articles/PMC10101678/ /pubmed/37042849 http://dx.doi.org/10.1080/07853890.2023.2190618 Text en © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
spellingShingle Oncology
Wang, Yan
Mao, Yiwen
Wang, Caizhi
Jiang, Xuefeng
Tang, Qionglan
Wang, Lingling
Zhu, Jialei
Zhao, Mengqiu
RNA methylation-related genes of m6A, m5C, and m1A predict prognosis and immunotherapy response in cervical cancer
title RNA methylation-related genes of m6A, m5C, and m1A predict prognosis and immunotherapy response in cervical cancer
title_full RNA methylation-related genes of m6A, m5C, and m1A predict prognosis and immunotherapy response in cervical cancer
title_fullStr RNA methylation-related genes of m6A, m5C, and m1A predict prognosis and immunotherapy response in cervical cancer
title_full_unstemmed RNA methylation-related genes of m6A, m5C, and m1A predict prognosis and immunotherapy response in cervical cancer
title_short RNA methylation-related genes of m6A, m5C, and m1A predict prognosis and immunotherapy response in cervical cancer
title_sort rna methylation-related genes of m6a, m5c, and m1a predict prognosis and immunotherapy response in cervical cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101678/
https://www.ncbi.nlm.nih.gov/pubmed/37042849
http://dx.doi.org/10.1080/07853890.2023.2190618
work_keys_str_mv AT wangyan rnamethylationrelatedgenesofm6am5candm1apredictprognosisandimmunotherapyresponseincervicalcancer
AT maoyiwen rnamethylationrelatedgenesofm6am5candm1apredictprognosisandimmunotherapyresponseincervicalcancer
AT wangcaizhi rnamethylationrelatedgenesofm6am5candm1apredictprognosisandimmunotherapyresponseincervicalcancer
AT jiangxuefeng rnamethylationrelatedgenesofm6am5candm1apredictprognosisandimmunotherapyresponseincervicalcancer
AT tangqionglan rnamethylationrelatedgenesofm6am5candm1apredictprognosisandimmunotherapyresponseincervicalcancer
AT wanglingling rnamethylationrelatedgenesofm6am5candm1apredictprognosisandimmunotherapyresponseincervicalcancer
AT zhujialei rnamethylationrelatedgenesofm6am5candm1apredictprognosisandimmunotherapyresponseincervicalcancer
AT zhaomengqiu rnamethylationrelatedgenesofm6am5candm1apredictprognosisandimmunotherapyresponseincervicalcancer